Creating the World's
Most Durable Heart Valve
Through Better Science & Better Design

ADAPT® is proven not to calcify over 10 years

Better Hemodynamics & Better Leaflet Performance

The Right...
Opportunity
Time
Technology

To those who say “we must accept limitations” we say:
Bring it onWe are relentless in our pursuit of excellence because patients need durable solutions now.

Latest News
FNN Online Investor Event
Anteris Technologies (ASX:AVR) Presentation FNN Online Investor Event
Notice of Extraordinary General Meeting
To be held 19th March 2021
MST Access - Q4 Results: Fresh Funds Available
Trials progressing well
CEO Wayne Paterson is interviewed by 180 Markets
CEO Wayne Paterson interview with 180 Markets
Anteris Technologies (ASX:AVR) nabs $20M funding package
CEO W. Paterson discusses the new funding package and upcoming FDA activities
Anteris set the stage in 2020 to prepare for DurAVR™ THV to be implanted in humans in 2021
""
Anteris presenting at the Switzer Small & Micro-Cap Conference
CEO Wayne Paterson provided a company overview and discussed the strategic direction of Anteris, followed by a brief Q&A session with investors. The event was hosted by Peter Switzer and attendees had the opportunity to hear from ASX-listed small & micro-cap companies across a range of different sectors.
Bioshares November 2020 Report
Positive Data from First Five Patients in 15 Patient Pilot Study
Anteris Technologies CEO hails 'very good results' from DurAVR™ human study
CEO Wayne Paterson is interviewed by Proactive Investors
CEO Wayne Paterson is interviewed by 180 Markets
CEO Wayne Paterson is interviewed by 180 Markets
The New Daily Podcast by John Elder with Prof Leon Neethling & Wayne Paterson
Anteris an Australian company’s innovative bid to transform heart valve technology
DurAVR™ Key Opinion Leader Summary
DurAVR™ Key Opinion Leader Summary